Holen Sie sich die Stockscreener-App
66.90
1.02%
-0.69
Handel nachbörslich:
67.18
0.28
+0.42%
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt AZN?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Astrazeneca PLC Aktie (AZN) Neueste Nachrichten
Malignant Pleural Mesothelioma Market Poised for Growth Across the 7MM During the Study Period (2020–2034) Amid Advances in Immunotherapy and Targeted Drugs | DelveInsight - GlobeNewswire Inc.
Press Release Distribution & PR Platform - ACCESS Newswire
Omeprazole Market Is Booming Worldwide 2025-2032 | Astrazeneca Plc., Sandoz, Inc., Mylan N.V. - openPR.com
Should You Buy, Sell Or Hold AstraZeneca Stock Before Q1 Earnings? - Barchart.com
AstraZeneca's Enhertu, pertuzumab combo improves breast cancer treatment in trial - Seeking Alpha
Should You Buy, Sell or Hold AstraZeneca Stock Before Q1 Earnings? - Yahoo
AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients - Yahoo Finance
ENHERTU Plus Pertuzumab Demonstrated Highly Statistically Significant And Clinically Meaningful Improvement In Progression-Free Survival Versus. THP As 1st-Line Therapy For Patients With HER2+ Metastatic Breast Cancer - marketscreener.com
AstraZeneca (AZN) Highlights Promising Trial Results for Enhertu in Breast Cancer Treatment | AZN Stock News - GuruFocus
AstraZeneca Touts Positive Survival Data for Enhertu Combo in Broad Breast Cancer Population - marketscreener.com
AstraZeneca, Daiichi Sankyo's Breast Cancer Drug Shows High-level Results in Late-stage Trial - marketscreener.com
Vasculitis Market Overall Study Report 2025-2032 | AstraZeneca - openPR.com
AstraZeneca Unit Hit With Antitrust Suit Over Soliris - Law360
AstraZeneca Subsidiary Accused of Soliris Drug Market Monopoly - Bloomberg Law News
AstraZeneca unit sued over alleged monopoly on blockbuster drug Soliris - Reuters
AstraZeneca Unit Faces US Class Action Lawsuit Alleging Misuse of Soliris Patent - marketscreener.com
AstraZeneca Should Get Fired Worker’s Vaccine Bias Case Trimmed - Bloomberg Law News
BNP Paribas Exane sets AstraZeneca stock to outperform, PT at GBP115 - Investing.com UK
Is AstraZeneca PLC (AZN) the Best Pharma Stock to Buy for Long Term Growth? - Insider Monkey
European pharma companies issue demands to stay in EU ahead of expected US tariffs - MarketScreener
Stock Watch: Disappointing ACC Share Price Reactions For AstraZeneca And Lilly - insights.citeline.com
AstraZeneca Pharma India surrenders marketing authorisation for specific indication of Olaparib - Medical Dialogues
Is AstraZeneca (AZN) The Best UK Stock to Buy According to Billionaires? - Yahoo Finance
The Zacks Analyst Blog AbbVie's, Rinvoq and AstraZeneca's and Novartis - Nasdaq
AstraZeneca | Pharmaceuticals, Vaccines, & Facts - Britannica
AstraZeneca : India's Serum Institute asks government for $403 million to boost AstraZeneca vaccine output - marketscreener.com
NICE recommends new combination breast cancer drug - MarketScreener
astrazeneca shareholders approve all resolutions at agm - Investing.com
Astrazeneca PLC Says All Resolutions Passed At AGM - MarketScreener
AstraZeneca’s AGM Approves All Resolutions, Marks Board Changes - TipRanks
Drug Tariffs Will Harm Patients, AstraZeneca Chairman Says - Bloomberg.com
AstraZeneca (AZN) Gains Momentum with EU Drug Approvals - GuruFocus
AstraZeneca's quarterly earnings may undershoot; tariffs and a trade war pose the bigger obstacle - Proactive financial news
AstraZeneca and GSK retain defensive qualities, but tariff assault on sector could change that - Proactive Investors
GLP-1 Market Top PlayersAstraZeneca, Biolingus, Boehringer Ingelheim, D&D Pharmatech. - openPR.com
Down 28% in 8 months, is AstraZeneca’s share price too cheap for me to pass up right now? - Yahoo
AstraZeneca (AZN) Gains EU Nod for Imfinzi Combo in NSCLC Treatm - GuruFocus
AstraZeneca (AZN) Gains EU Approval for Expanded Enhertu Use in Breast Cancer - GuruFocus
AstraZeneca Settles Covid-Shot Suit With Christian Salesman - Bloomberg Law News
AstraZeneca Blocks Generics Ahead Of Patent Dispute - Law360
Why Roche Holding, Eli Lilly, and AstraZeneca Stocks Dropped Today - Mitrade
AstraZeneca stock touches 52-week low at $61.76 - Investing.com
AstraZeneca stock touches 52-week low at $61.76 By Investing.com - Investing.com India
UK Regulator Approves Expanded Use of AstraZeneca's Targeted Cancer Therapy - MarketScreener
UK Approves Indication Extension for AstraZeneca-Daiichi Sankyo's Cancer Drug Enhertu - marketscreener.com
Barclays Keeps AstraZeneca at Overweight on Potential to Withstand Tariff Storm - MarketScreener
AstraZeneca (AZN) Prepares for Upcoming Earnings Amid Stock Decl - GuruFocus
Trending tickers: Apple, Advanced Micro Devices, Ford, BP and AstraZeneca - Yahoo
FTSE 100 sinks as tariffs kick in with 104% for China; AstraZeneca and GSK slumpMarket Report - Proactive financial news
AstraZeneca's Camizestrant Shows Promise in SERENA-6 Breast Canc - GuruFocus
Trump inflicts £14bn blow to the UK drug sector with tariff threat - Proactive Investors
Astrazeneca (AZN) Stock Moves -1.35%: What You Should Know - Yahoo Finance
Daiichi Sankyo and AstraZeneca get EU approval for Datroway - Seeking Alpha
Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - GlobeNewswire Inc.
Relative Strength Alert For AstraZeneca - Nasdaq
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):